Evidence map›Paper›PMID 42766433›Full record

ArticleJournal of cellular and molecular medicine2026

In Vitro Effects of Anaesthetic Compounds on a Panel of Solid Tumour Cell Lines-An Exploratory Study.

Olga Grajdieru, Alexandru Cristian Sabo, Adrian Bogdan Tigu, Andrei Ivancuta, Cristian Silviu Moldovan, Andrada Uhl, Miruna Cristina Ungurenasu, Andrada-Ioana Balmez, Ada Moisescu, Simina Pîrv and 5 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Olga GrajdieruDepartment of Anaesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Alexandru Cristian SaboDepartment of Chemistry and Biochemistry, USAMV Cluj-Napoca, Cluj-Napoca, Romania.
Adrian Bogdan TiguDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.ORCID https://orcid.org/0000-0001-9397-0791
Andrei IvancutaDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Cristian Silviu MoldovanDepartment of Nanosciences, MEDFUTURE Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Andrada UhlDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Miruna Cristina UngurenasuDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Andrada-Ioana BalmezDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ada MoisescuDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Simina PîrvDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Madalina NistorDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ximena-Maria MuresanDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Diana CenariuDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ciprian TomuleasaDepartment of Personalized Medicine and Rare Diseases, MEDFUTURE-Institute for Biomedical Research, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Catalin ConstantinescuDepartment of Anaesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Funding

Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca 32154/25/16.12.2024Young Research Teams 2023 PN-IV-P2-2.1-TE-2023-0483
6 · The paper itself

Abstract

Anaesthetic agents are essential for surgical procedures, yet their potential role on tumour cell biology remains incompletely understood. Emerging evidence suggests that these compounds can act both as protumor and antitumor agents, influencing cellular processes such as proliferation, migration and cell death mechanisms. Eight commonly used anaesthetic compounds were tested on five tumour cell lines-A549Luc2, HCT116Luc2, HUH7, MDAMB231Luc2 and SKMEL28Luc2. Cytotoxicity was assessed by MTT assay, while morphological changes were analysed using confocal fluorescence microscopy. Functional assays were used for wound healing, colony formation, flow cytometry for cell death and cell cycle and gene expression profiling was assessed by RT-qPCR. Morphological evaluation revealed profound compound-specific alterations, including mitochondrial fragmentation, nuclear condensation, osmotic swelling and cell structure alterations. Lidocaine and ropivacaine induced stress fibre formation and swelling, while tunnelling nanotubes were observed as signs of cellular stress. The structural changes are correlated with impaired migration, reduced colony formation and necrosis-dominated cell death. Gene expression analysis showed heterogeneous changes of apoptotic and cell cycle regulators, with caspase upregulation and NF-kB activation in specific cases. Anaesthetic agents exert pleiotropic, cell-line-dependent effects, primarily inhibiting tumour growth and motility in our cell models through structural destabilization and stress signalling. These findings underscore the need for advanced models to clarify clinical relevance and to confirm the best choice of anaesthesia technique tailored to the patient's specific cancer type.

Indexed as

AnestheticsNeoplasmsApoptosisCell CycleCell DeathCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansAnestheticsanaesthetic compoundscell deathmorphological and structural changespain controltumour cells

Identifiers

PMID42766433
PMCPMC13592546

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.